Original filename: Untitleddocument.pdf
This PDF 1.5 document has been generated by / Skia/PDF m53, and has been sent on pdf-archive.com on 30/06/2016 at 16:36, from IP address 128.180.x.x.
The current document download page has been viewed 184 times.
File size: 82 KB (4 pages).
Privacy: public file
Download original PDF file
The Van Demark Daily
“Fuck me I’m gay as shit, OMEX to $30”
55M Market cap lmao
Lose $ daily
Positive revenue growth (10%)
17M in cash but 178M in debt
8% short float
Volume is shit
No recent analyst updates because no one gives a shit about this company
Compared to their major competitors they have A LOT less debt
They process wood or some shit?
Company hasnt been profitable since 2011 lmao
Lose more money every year
What the fuck is this shit? Stay far away.
Financials are decent alright not like you give a shit anyway
Although everyone and their mother wants to short this company at 24% short float
Fucking surprise, volume sucks
Wow these guys actually are somewhat, nope jk they fucking lose money every year
Oh for fucks sake is biotech
Their new drug Solithromycin got fast tracked thats a big deal
Data looked solid meet all goals
Dam FDA isnt going to have their decision till the end of 2016
They have some phase 3 data for something else TODAY so maybe buy the dip?
Keep it on your radar, but its going to get a lot worse before it gets better.
2B Market cap biotech off me pls
Decent financials but they fucking lose $ every year
They make fucking vaccines
Respiratory Syncytial Virus Fprotein nanoparticle vaccine could be FTB
In phase 3 trials
Results out September 30th
Fast tracked FTB
This is my favorite so far, a huge fucking YOLO
What the fuck is this shit
50% fucking short float thats unreal
Literally burning money
Like im not even kidding they blow at making money
Got upgraded by Morgan Stanly only to get downgrades 15 days later lmao
Fuck off with the shitty biotech
I can’t find their pipeline and their only drug already got full approval
Fuck em boring as shit
Financials are all over the place
Dont make $ and 5B in debt but they have 6B in cash sooooooo
QRTly rev is 16% lol
Not a big fan on banks becuase they have no events to play
I mean you can play earnings reports but FUCK EARNINGS REPORTS
My YOLO opportunities:
Shits had huge volume recently and lots of 35$ calls for January
Buyout would cost around 30M
Google is the only real contender
This one is risky as fuck
Just put out a new graphics card that was real hyped up
Shits gona get recalled because it might set ur computer on fire
Buy the dip (dont buy skoal crisp tho)
Lots of story comming up…
There has been a lot of hype surrounding MSTX. Here is my quick DD on MSTX
and Vepolaxamer, A perspective from a heavy background in science although
just a newbie in finance ( I just started investing about a week ago). I don’t know
how many people actually understand the drug and the trials or are most people
just buying in on the hype.
MST188 is a drug that hopes to reduce pain during a sickle crisis.
Physiologically, the sickled red blood cells are sickled shape, causing it to carry
reduced oxygen and the sickle shape makes it harder to travel though blood
vessels, it will eventually collide against the walls of a blood vessel and stay put.
The damaged RBCS will have sticky open sores that cause them to stick to one
another accumulating a blood dam and thus preventing tissues from receiving
adequate oxygen. This inadequate lack of oxygen tissue is what causes the pain.
The current therapy focuses on eliminating symptoms by inducing more fluids.
In the simplest form,Vepolaxamer or MST188 is targeting the source of pain by
its action of mechanism which is attaching directly on to a cell membrane with it’s
sticky side, and having the surfactant surface on the other end to avoid RBCS
from sticking to one another, increasing blood flow and productively reducing
pain. The drug eventually leaves the membrane once the RBC repairs itself,
exiting the body by the kidneys.
Complete video here :
If you are interested in
seeing the animation of the drug inside the body.
FDA conditional success rates for drugs in Phase III of clinical trials is about
64%. According to this site:
MSTX revenues, operating costs, and stability depends heavily on the success of
this drug. The drug effect might show minor results, a symptom reducing drug but
not anywhere close to a breakthrough. It will not replace hydroxyurea, the hail
mary of sickle cell drugs for the last 25 years. I could however see Vepolaxamer
working in conjunction with hydroxyurea ( if it passes phase III) to stop the
production of the sickle cells and to alleviate the pain of ones that are sickled
At a quick glance the trend seems to show support around $0.40 and a
resistance at $0.45. It most likely wont break the resistance point until after the
release of a successful trial. Until then we’re all just going to be clenching our
assholes waiting for news.
Conclusion: Buy YOLO shares, as the data points towards success. I would not
long this stock. My guess is this drug is just meant to bring in quick revenue for
the company if it succeeds but not for long term growth.
I’m positive there is a lot of people here who have a ton of biotech experience
and science backgrounds. Please do get in on the conversation and correct me if
I am wrong.
Eh fuck it I got 400 shares
Safe Buys / Long Plays